University Hospital
Toulouse, 31059, France
Location status: Recruiting
NCT Number: NCT06387654
The aim of this project is to start a biological and clinical collection of patients presenting autoimmune, dysimmune or auto-inflammatory dermatological diseases. This collection will provide appropriate biological samples to identify new biomarkers and to be accessible to the medical, scientific and industrial communities for the identification of new therapeutic strategies.
Interested in participating?
Request Info6 year–99 year
All sexes
Observational
Toulouse, 31059, France
Location status: Recruiting
Autoimmune diseases include around a hundred different clinical entities which are for the most part rare pathologies but which, in combination, concern 5-8% of the adult population with a strong female predominance (FAI²R: the disease chain rare autoimmune and auto-inflammatory drugs, fai2r.org). The common denominator of all these diseases is based on the breakdown of self-tolerance which is the origin of self-reactivity and whose physiopathological mechanisms are still not fully understood, which generates numerous cross-sectional or fundamental studies. In addition to this complexity, there are significant inter-individual variabilities which lead to the definition of subgroups of patients on the basis of the clinical-biological profile and / or the response to treatments. Consequently, and in view of the need to establish the diagnosis early and then to propose the best treatment in the perspective of an individualized medicine, the clinical, biological and genetic characteristics of these subgroups of patients must be explored in order to improve diagnostic and therapeutic capacities.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Skin damage of documented or probable autoimmune, dysimmune or autoinflammatory origin.
The patients included may be adults or children, and will be:
Patients with dermatological damage whose autoimmune, dysimmune or auto-inflammatory origin is suspected
Exclusion criteria
Blood will be taken in larger quantity
blood, CSF, saliva, stools, urine, other biological fluids and tissue biopsies, hair follicles
Time frame: Day 0 and through study completion, an average of 1 year
Blood sampling
Time frame: Day 0 and through study completion, an average of 1 year
Western blot or immunoprecipitation method
Time frame: Day 0 and through study completion, an average of 1 year
Proteomic analysis of sera and plasma samples at diagnosis and during follow up
Time frame: Day 0 and through study completion, an average of 1 year
Knock-out or knock-in animal models for one specific protein will be used to determine in vivo if the pathophysiological mechanisms of Dermatological Diseases can be induced by the abnormal expression of this protein.
Analysis of the phenotypic profiling of blood immune cells by multicolor fluorescence-activated cell sorter (FACS) analysis and of the transcriptomic profiling of blood immune cells by RNA sequencing
Time frame: Day 0 and through study completion, an average of 1 year
Exploring blood cell populations before and after cell therapy with flow cytometry
Contact information is provided by the study sponsor or research team.
University Hospital, Toulouse
Other
Constitution of a Collection of Biological Samples With the Aim of Carrying Out Clinico-biological and Physiopathological Investigations of Autoimmune, Dysimmune or Auto-inflammatory Dermatological Diseases
Acronym: TekAPo
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06599411
Active Leprosy, Atopic Dermatitis
Paris, France
View Trial DetailsNCT06073613
Atopic Dermatitis, Autoimmune Bullous Dermatosis
Ho Chi Minh City, Vietnam
View Trial DetailsNCT06037187
Autoimmune Bullous Dermatosis
Omaha, Nebraska, United States
View Trial DetailsNCT01631617
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Dermatitis
Bethesda, Maryland, United States
View Trial Details